Loading...

Selexipag in the management of pulmonary arterial hypertension: an update

Selexipag is a compound that was designed to overcome the issues associated with oral administration of prostanoid compounds, beraprost and treprostinil in the treatment of pulmonary hypertension (PAH). As a selective IP agonist, it was designed to avoid the off-target prostanoid effects especially...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Drug Healthc Patient Saf
Main Authors: Coghlan, J Gerry, Picken, Christina, Clapp, Lucie H
Format: Artigo
Sprog:Inglês
Udgivet: Dove 2019
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6689562/
https://ncbi.nlm.nih.gov/pubmed/31496830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DHPS.S181313
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!